Objective: To investigate the anti-obesity effect of the adipokine zinc-a 2 -glycoprotein (ZAG) in rats and the mechanism of this effect. Subjects: Mature male Wistar rats (540±83 g) were administered human recombinant ZAG (50 mg per 100 g body weight given intravenously daily) for 10 days, while control animals received an equal volume of phosphate-buffered saline (PBS). Results: Animals treated with ZAG showed a progressive decrease in body weight, without a decrease in food and water intake, but with a 0.4 1C rise in body temperature. Body composition analysis showed loss of adipose tissue, but an increase in lean body mass. The loss of fat was due to an increase in lipolysis as shown by a 50% elevation of plasma glycerol, accompanied by increased utilization of non-esterified fatty acids, as evidenced by the 55% decrease in plasma levels. Plasma levels of glucose and triglycerides were also reduced by 36-37% and there was increased expression of the glucose transporter 4 in both skeletal muscle and adipose tissue. Expression of the lipolytic enzymes adipose triglyceride lipase and hormone-sensitive lipase in the white adipose tissue (WAT) were increased twofold after ZAG administration. There was almost a twofold increased expression of uncoupling proteins 1 and 3 in brown adipose tissue and WAT, which would contribute to increased substrate utilization. Administration of ZAG increased ZAG expression twofold in the gastrocnemius muscle, BAT and WAT, which was probably necessary for its biological effect. Conclusion: These results show that ZAG produces increased lipid mobilization and utilization in the rat.
Introduction
Obesity is a major problem of the twenty-first century, with up to 25% of adults considered to be obese. 1 Our previous studies in mice 2, 3 have identified zinc-a 2 -glycoprotein (ZAG), a soluble protein with sequence homology to histocompatibility antigens, 4 as a potential treatment for obesity. ZAG was originally isolated as a lipid-mobilizing factor responsible for fat loss in cancer cachexia and was found to be expressed by tumours that produced a decrease in carcass lipids. 5 Subsequent studies showed ZAG to be produced by a range of normal tissues including liver, heart and lung, as well as white adipose tissue (WAT) and brown adipose tissue (BAT), 6 suggesting that it was a new adipokine. Moreover, ZAG expression in liver, WAT and BAT was upregulated during the phase of weight loss in mice bearing a cachexiainducing tumour, with the largest increase (10-fold) being in WAT. 6 Both glucocorticoids and b3 agonists increased the expression of ZAG mRNA in 3T3-L1 adipocytes 6 and glucocorticoids are probably responsible for the increase in ZAG expression seen in the adipose tissue of cachetic mice. 7 In contrast with cachexia, the adipose tissue of obese subjects shows only one-third the expression of ZAG seen in non-obese individuals. 8 This is at least partly due to increased tumour necrosis factor-a production in the adipocytes of obese subjects. 9 Recent studies 9 show the ZAG mRNA level in visceral and subcutaneous fat of human subjects to be negatively correlated with BMI and fat mass, as well as parameters of insulin resistance. Studies using a mouse model of obese type 2 diabetes have also identified ZAG as a possible candidate gene for obesity. 10 The effect of ZAG depletion has been studied in mice with inactivation of both ZAG alleles by gene targeting. 11 ZAG depletion led to an increase in body weight compared with wild-type mice, especially when the animals were fed a high-fat diet, while there was a decreased lipolytic activity in epididymal adipocytes in response to isoprenaline, a b3-agonist, and agents that increase cyclic AMP. 11 These results suggest that loss of ZAG may be responsible for obesity in some individuals.
To date all studies on the lipid-mobilizing effect of ZAG have been carried out in mice, 2,3 using human ZAG, although the identities in amino-acid sequence of ZAG between mouse and humans is only 58.6%. 12 As the sequence homology between rat and mouse is 88.5%, 12 this suggests that if human ZAG binds to the mouse receptor it should also be effective in the rat. The current study investigates the anti-obesity effect of human ZAG in mature male Wistar rats.
Materials and methods

Materials
FreeStyle media was purchased from Invitrogen (Paisely, UK). . Polyclonal rabbit antibody to mouse b-actin and the triglyceride assay kit were purchased from Sigma Aldrich (Dorset, UK). Peroxidase-conjugated goat anti-rabbit and rabbit anti-mouse polyclonal antibodies, hybond-A nitrocellulose membranes and enhanced chemiluminescence development kits were from GE Healthcare (Bucks, UK). A WAKO colorimetric assay kit for measurement of non-esterified fatty acids was purchased from Alpha Laboratories (Hampshire, UK) and a mouse insulin ELISA kit was purchased from DRG (Marburg, Germany). Glucose measurements were made using a plasma glucose assay kit (Boots, Nottingham, UK).
Production of recombinant ZAG HEK293F cells were transfected with full-length human ZAG cDNA in the expression vector pcDNA 3.1 and maintained in FreeStyle medium under an atmosphere of 5% CO2 in air at 37 1C. ZAG was secreted into the medium, which was collected, and maximal protein levels (16 mg ml
À1
) were obtained after 14 days of culture. To purify ZAG, media (200 ml) was centrifuged at 700 g for 15 min to remove cells and concentrated into a volume of 1 ml sterile phosphate buffered saline (PBS) using an Amicon Ultra-15 centrifugal filter with a 10-kDa cutoff. The concentrate (about 2 mg protein) was added to 2 g DEAE cellulose suspended in 20 ml of 10 mM Tris, pH 8.8 and stirred for 2 h at 4 1C. The DEAE cellulose bound ZAG and it was sedimented by centrifugation (1500 g for 15 min) and the ZAG was eluted by stirring with 20 ml of 10 mM Tris, pH 8.8, containing 0.3 M NaCl for 30 min at 4 1C. The eluate was washed and concentrated into a volume of 1 ml in sterile PBS using an Amicon centrifugal filter. The purified ZAG was free of endotoxin, as determined with a LAL Pyrogent single test kit (Lonza, Bucks, UK) and was stored in PBS at 4 1C. Freezing destroys activity.
Lipolytic activity in rat adipocytes
White adipocytes were prepared from finely minced epididymal adipose tissue of male Wistar rats (400 g) using collagenase digestion, as described. 13 Lipolytic activity was determined by incubating 10 5 -2 Â 10 5 white adipocytes for 2 h in 1 ml Krebs-Ringer bicarbonate buffer, pH 7.2, with the concentrations of ZAG indicated in Figure 1 , and the extent of lipolysis was determined by measuring the glycerol released. 14 Spontaneous glycerol release was measured by incubating adipocytes alone. Lipolytic activity was expressed as mmol glycerol released per 10 5 adipocytes every 2 h.
Glucose uptake into adipocytes Isolated white or brown adipocytes (5 Â 10 4 ) were washed twice in 1 ml Krebs-Ringer bicarbonate buffer (KRB), pH 7.2, and further incubated for 10 min at room temperature by shaking in 0.5 ml KRB containing 18. Figure 1 Lipolytic activity of human ZAG in isolated rat epididymal adipocytes, compared with isoprenaline (10 mM) in the absence or presence of SR59230A (10 mM) or anti-ZAG antibody (1:1000) (IgG). Each value is an average of five separate studies. Differences from control are shown as b, Po0.01 or c, Po0.001, while differences from ZAG alone are indicated as d, Po0.05; e, Po0.01; or f, Po0.001.
were allowed to float to separate them from the medium and they were washed three times with 1 ml KRB, lysed by addition of 0.5 ml 1 M NaOH, and left for at least 1 h at room temperature before the radioactivity was determined by liquid scintillation counting.
Glucose uptake into gastrocnemius muscle Gastrocnemius muscles were incubated in Krebs-Henseleit bicarbonate buffer for 45 min at 37 1C and then incubated for a further 10 min in 5 ml Krebs-Henseleit buffer containing 185 MBq 2-(1-14 C) deoxy-D-glucose and non-radioactive 2-deoxy-D-glucose to a final concentration of 0.1 mM. The muscles were then removed and washed in 0.9% NaCl for 5 min, followed by dissolution in 0.5 ml of 1 M NaOH and the radioactivity was determined by liquid scintillation counting.
Animal studies
Mature male Wistar rats (1 year old from our own colony) weighing 540 ± 82.5 g were housed individually in a temperature-controlled environment (19-22 1C) and treated once daily intravenously, with either ZAG in PBS (100 ml) (50 mg per 100 g body weight) or PBS (100 ml) as a control. The dose of ZAG administered was the same on a body weight basis as that previously shown to be effective in ob/ob mice. Previous studies 3 indicated no dose-response relationship once a threshold dose had been achieved. This dose level is, therefore, likely to be optimal. Both food and water intake and body weight were measured daily. Animals were given free access to food (Special Diet Services, Essex, UK) and water ad libitum. The animal experiment was carried out under the welfare conditions imposed by the British Home Office. Body temperature was measured by the use of a rectal thermometer (RS Components, Northants, UK). After 10 days of treatment, the animals were terminated by cardiac puncture under terminal anaesthesia and the body composition was determined. Animals were heated to 80-90 1C for 7 days until constant weight was achieved. The water content was then determined from the difference between the wet and the dry weight. Lipids were extracted from the dry carcass using a sequence of chloroform:methanol (1:1), ethanol:acetone (1:1) and diethyl ether (120 ml of each) as described by Lundholm et al. 16 The solvents were evaporated and the fat was weighed. The non-fat carcass mass was calculated as the difference between the initial weight of the carcass and the weight of water and fat.
Western blotting
Samples of epididymal WAT, BAT and gastrocnemius muscle, excised from rats treated with ZAG or PBS for 10 days, were homogenized in 0.25 M sucrose, 1 mM HEPES, pH 7.0, and 0.2 M EDTA, and then centrifuged for 10 min at 4500 r.p.m. Samples of cytosolic protein (10 mg) were resolved on 12% sodium dodecylsulphate polyacrylamide gel electrophoresis and the proteins were then transferred onto 0.45 mm nitrocellulose membranes, which had been blocked with 5% Marvel in Tris-buffered saline, pH 7.5, at 4 1C overnight, and after four 15-min washes with 0.1% Tween in PBS, incubation with the secondary antibody was performed for 1 h at room temperature. Development was by enhanced chemiluminescence. Western blots were quantitated by densitometric analysis using a computer programme called Image J.
Statistical analysis
Results were expressed as mean±s.e.m. Differences were determined by one-way ANOVA, followed by Tukey-Kramer multiple comparison test. P-values less than 0.05 were considered significant.
Results
The lipolytic effect of human ZAG towards rat epididymal adipocytes in comparison with isoprenaline is shown in Figure 1 . At concentrations of 465 and 700 nM, ZAG produced a significant increase in glycerol release, which was attenuated by anti-ZAG monoclonal antibody, showing the specificity of the action. The extent of lipolysis in rat adipocytes was similar to that previously reported in the mouse. 3 As in the mouse, the lipolytic effect of ZAG was completely attenuated by the b3-adrenergic receptor (b3-AR) antagonist SR59230A, 17 suggesting that the action of ZAG was mediated through b3-AR. These results suggest that ZAG may be effective in inducing fat loss in rats.
The effect of single daily intravenous injection of ZAG (50 mg per 100 g body weight) on the body weight of mature male Wistar rats (540 ± 83 g) is shown in Figure 2a . Compared with control rats administered the same volume of solvent (PBS), rats administered ZAG showed a progressive decrease in body weight, such that after 10 days, whereas rats treated with PBS showed a 13-g increase in body weight, animals treated with ZAG showed a 5-g decrease in body weight (Table 1 ). There were no behavioural or mobility changes between the groups and no evidence of antibody production as evidenced by western blotting of human ZAG using serum for rats treated for 10 days diluted 1:5 and 1:10. There was also no difference in food (ZAG: 102 ± 32 g; PBS: 98±25 g) or water (ZAG: 135±35 ml; PBS: 125±25 ml) intake between the two groups during the course of the study, but ZAG-treated animals showed a consistent 0.4-1C elevation in body temperature, which was significant within 24 h of the first administration of ZAG (Figure 2b) , suggesting an elevated energy expenditure. An alternative explanation that this was due to an immune response in the rat, owing to administration of a human protein, was thought less likely, because of the short time of administration, lack of a progressive response and no evidence of anorexia caused by cytokine production. There is a possibility, which has not been investigated, that the increase in body temperature was due to peripheral vasoconstriction. Body composition analysis (Table 1) showed that the loss of body weight induced by ZAG was due to a loss of carcass fat, which was partially offset by a significant increase in lean body mass. There was a 50% increase in plasma glycerol concentration in rats treated with ZAG (Table 2) , indicative of an increased lipolysis, but a 55% decrease in plasma levels of non-esterified fatty acids (NEFAs), suggesting an increased utilization. Plasma levels of glucose and triglycerides were also reduced by 36-37% (Table 2) , also suggesting an increased utilization. There was a significant increase in the uptake of 2-deoxygluocse into epididymal adipocytes of rats treated with ZAG for 10 days, which was increased in the presence of insulin (Figure 2c ). However, there was no significant difference in glucose uptake into adipocytes from ZAG-or PBS-treated animals in the presence of insulin (Figure 2c ). There was a small, nonsignificant increase in glucose uptake into gastrocnemius muscle and BAT of rats treated with ZAG in comparison with PBS controls, but a significant increase in uptake in the presence of insulin (Figure 2d) . The response to insulin is less Zinc-a 2 -glycoprotein and lipid loss ST Russell and MJ Tisdale than that experienced in younger, less fat animals. These results suggest that the decrease in blood glucose is due to increased utilization by BAT, WAT and skeletal muscle, and this is supported by an increased expression of glucose transporter 4 in all the three tissues ( Figure 3) .
ZAG administration increased expression of the uncoupling proteins (UCP)1 and 3 in both BAT and WAT by about twofold (Figures 4a and b) . There was no difference in the extent of induction in WAT and BAT, although basal expression of UCP1 in WAT was very low compared with BAT. The specificity of the antibodies was determined by western blotting of the gastrocnemius muscle, which is known to contain UCP3, but not UCP1 (Figure 4 ). An increased expression of UCP1 would contribute to increased substrate utilization if it were activated. In rats treated with ZAG, there was also an increased expression of the lipolytic enzymes adipose triglyceride lipase (ATGL) and hormonesensitive lipase (HSL) in epididymal adipose tissue ( Figure 5 ), again with a twofold increase. ATGL is mainly responsible for the hydrolysis of the first ester bond in a triacylglycerol molecule forming diacylgylcerol, while its conversion to monacylglycerol is carried out by HSL. Expression of ZAG was also significantly increased in the skeletal muscle (Figure 6a ), WAT (Figure 6b ) and BAT (Figure 6c ) of rats treated with ZAG for 10 days, showing that exogenous ZAG boosts its own production in peripheral tissues.
There was a significant reduction in the expression of the phosphorylated forms of both dsRNA-dependent protein kinase (PKR) and eukaryotic initiation factor 2 on the asubunit in the gastrocnemius muscle of rats administered ZAG, while the total amount did not change (Figure 7) . Similar changes have been observed in ob/ob mice administered ZAG (unpublished results) and were consistent with a depression of protein degradation and increase in protein synthesis in the skeletal muscle. 18 
Discussion
ZAG has been attributed a number of biological roles, 19 but its role as an adipokine regulating lipid mobilization and utilization is most important in regulating body composition. Our previous studies 2 identified ZAG as a lipidmobilizing factor capable of inducing lipolysis in white adipocytes of the mouse in a GTP-dependent process, similar to that induced by lipolytic hormones. This study shows that ZAG has a similar lipolytic effect in rat adipocytes and, moreover, produces a decrease in body weight and carcass fat in mature male rats, despite the fact that the sequence homology between rat and human ZAG is only 59.4%. 12 The results of this study show that ZAG administration to the rat also increases the expression of ATGL and HSL. ATGL may be important in excess fat storage in obesity, as ATGL knockout mice have large fat deposits and reduced NEFA release from WAT in response to isoproterenol, although they did display normal insulin sensitivity. 20 In contrast, HSL-null mice, when fed a normal diet, had body weights similar to wild-type animals. 21 However, expression of both ATGL and HSL are reduced in human WAT in the obese insulin-resistant state compared with the insulin-sensitive state, and weight reduction also decreased mRNA and protein levels. 22 Stimulation of lipolysis alone would not deplete body fat stores, as without an energy sink, the liberated NEFA would be resynthesized back into triglycerides in adipocytes. 23 To reduce body fat, ZAG not only increases lipolysis, as shown by an increase in plasma glycerol, but also increases the lipid utilization, as shown by the decrease in plasma levels of triglycerides and NEFA. This energy is channelled into heat, as evidenced by the 0.4 1C rise in body temperature in rats treated with ZAG. The increased energy utilization most likely arises from the increased expression of UCP1, which has been shown in both BAT and WAT after administration of ZAG. An increased expression of UCP1 would be expected to decrease plasma levels of NEFA, as they are the primary substrates for thermogenesis in BAT. 24 BAT also has a high capacity for glucose utilization, 25 which could partially explain the decrease in blood glucose. In addition, there was an increased expression of GLUT-4 in skeletal muscle and WAT, which helps mediate the increase in glucose uptake in the presence of insulin. 26 In mice treated with ZAG, there was an increased glucose utilization by brain, heart, BAT and gastrocnemius muscle and increased production of 27 There was also a threefold increase in oxygen uptake by BAT of ob/ob mice after ZAG administration. 2 Induction of lipolysis in rat adipocytes by ZAG is suggested to be mediated through a b3-AR, and the effect of ZAG on adipose tissue and lean body mass may also be due to its ability to stimulate the b3-AR. 28 Induction of UCP-1 expression by ZAG has been shown to be mediated through interaction with a b3-AR 29 and thus will be activated. The increased expression of UCP1 in WAT may also be a b3-AR effect through remodelling of brown adipocyte precursors, as occurs with the b3-AR agonist CL316,243. 30 Using knockout mice, the anti-obesity effect of b3-AR stimulation has been mainly attributed to UCP1 in BAT, and less to UCP2 and UCP3 through the UCP1-dependent degradation of NEFA released from WAT. 31 Glucose uptake into peripheral tissues of animals is stimulated by cold exposure, an effect also mediated through the b3-AR. 32 However, targeting the b3-AR has been more difficult in humans than in rodents, as b3-AR Figure 7 Expression of phosphorylated and total forms of PKR and eukaryotic initiation factor 2a in the gastrocnemius muscle of male Wistar rats treated with either PBS or ZAG for 10 days as shown in Figure 2 . Each lane contains protein from an individual animal. The densitometric analysis is the ratio of the phosphor to total forms, expressed as a percentage of the value for rats treated with PBS. c, Statistically significant from PBS control, Po0.001 by one-way ANOVA followed by Tukey-Kramer post-test.
